Safe Drugs Versus Innovative Drugs (Can We Have Both?)

Safe Drugs Versus Innovative Drugs (Can We Have Both?)

Bibliographic Details
Main Author:	Vera Lúcia Raposo
Format:	Article
Language:	English
Published:	Tabriz University of Medical Sciences 2020-05-01
Series:	Advanced Pharmaceutical Bulletin
Online Access:	https://apb.tbzmed.ac.ir/PDF/apb-27769

Similar Items

Sufficient blood, safe blood: can we have both?
by: Bönig Halvard, et al.
Published: (2012-03-01)

Magnesium in drugs: do we have enough information?
by: Maria Ángeles Campos Fernández de Sevilla, et al.
Published: (2014-11-01)

Woodland caribou management and industrial development in West Central Alberta: Can we have both?
by: Wayne Thorp
Published: (2012-03-01)

Skin Barriers in Dermal Drug Delivery: Which Barriers Have to Be Overcome and How Can We Measure Them?
by: Christian Gorzelanny, et al.
Published: (2020-07-01)

Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
by: James P. C. Coverdale, et al.
Published: (2019-03-01)

Platinum drugs and taxanes: can we overcome resistance?
by: Elena V. Sazonova, et al.
Published: (2021-06-01)

Bisphosphonate drug holidays: Can we recommend currently?
by: Vishal R Tandon, et al.
Published: (2014-01-01)

Fatal drug errors in anaesthesia: Can we override?
by: Amitabh Kumar, et al.
Published: (2014-01-01)

How can we prevent Adverse Drug reactions?
by: Saša Markovič
Published: (2010-04-01)

Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
by: Jeffrey L. Krajewski, et al.
Published: (2010-09-01)

Aptamers as Both Drugs and Drug-Carriers
by: Md. Ashrafuzzaman
Published: (2014-01-01)

Marina Shestakova:«We are happy that these drugs and technologies have come to us»
by: M. V. Shestakova
Published: (2018-03-01)

Are biological drugs safe in pregnancy?
by: A. Calligaro, et al.
Published: (2015-03-01)

What we have accomplished and what we can achieve
by: A. Morais
Published: (2014-03-01)

Laparoscopic training in colorectal surgery: can we do it safely?
by: Luiz Felipe de Campos Lobato, et al.
Published: (2013-01-01)

Two Decades of TB Drug Discovery Efforts—What Have We Learned?
by: Balachandra Bandodkar, et al.
Published: (2020-08-01)

Drug-Eluting Intra-Coronary Stents: Have We Got the Magic Bullet?
by: Bhatia V, et al.
Published: (2003-01-01)

Can we have a general theory of financial innovation processes? A conceptual review
by: Tamer Khraisha, et al.
Published: (2018-03-01)

Studies on the safe administration of drugs : evaluation and prevention of drug interactions
by: Whiting, Brian
Published: (1976)

Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?
by: Raphael Taiwo Aruleba, et al.
Published: (2020-07-01)

Adding Education to “Test and Treat”: Can We Overcome Drug Resistance?
by: Mo’tassem Al-arydah, et al.
Published: (2015-01-01)

COVID-19: Wait for a novel drug or act with the age old drug – Do we have a choice?
by: Pugazhenthan Thangaraju, et al.
Published: (2020-06-01)

Methamphetamine and MDMA: ‘Safe’ drugs of abuse
by: Allana M. Krolikowski, et al.
Published: (2014-03-01)

Procedure of safe handling with cytostatic drugs
by: Kodžo Dragan
Published: (2003-01-01)

Can We Provide Safe Training and Competition for All Athletes? From Mobile Heart Monitoring to Side Effects of Performance-Enhancing Drugs and MicroRNA Research
by: Łukasz A. Małek, et al.
Published: (2021-03-01)

When Can We Release the Amplatzer Ductal Occluder (ADO) Safely?
by: Mehdi Ghaderian, et al.
Published: (2015-10-01)

If We Cannot Have Both, Then Which Union Do We Choose? Scotland’s Options after ‘Brexit’
by: Simon J. Smith
Published: (2016-12-01)

If We Cannot Have Both, Then Which Union Do We Choose? Scotland’s Options after ‘Brexit’
by: Simon J. Smith
Published: (2016-12-01)

What have we learned from the War on Drugs? an assessment of Mexico's counternarcotics strategy
by: Shipley, Joe C.
Published: (2012)

Drug–drug interaction database for safe prescribing of systemic antifungal agents
by: Saarah Niazi-Ali, et al.
Published: (2021-04-01)

Why We Can't Have Our Facts Back
by: Noortje Marres
Published: (2018-07-01)

Increasing adverse drug reaction reporting-How can we do better?
by: Miri Potlog Shchory, et al.
Published: (2020-01-01)

Harm reduction and “Clean” community: can Viet Nam have both?
by: Khuat Thu, et al.
Published: (2012-07-01)

Implementation of Safe-by-Design for Nanomaterial Development and Safe Innovation: Why We Need a Comprehensive Approach
by: Annette Kraegeloh, et al.
Published: (2018-04-01)

Primum non nocere. Quomo sapere? [Firstly, do no harm. How can we know this?] Drug-eluting stents versus surgery
by: Álvaro Nagib Atallah

Drug Therapy For Preventing Ventricular Arrhythmia In Brugada syndrome: Do We Have The Answers Yet?
by: Shomu Bohora
Published: (2013-09-01)

Menopausal Hormone Therapy, can we safely use it in women with co-morbidities?
by: Duru Shah
Published: (2015-01-01)

Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.
by: Sajad Shahbazi, et al.
Published: (2016-01-01)

Can We Be Both Resilient and Well, and What Choices Do People Have? Incorporating Agency into the Resilience Debate from a Fisheries Perspective.
by: Sarah Coulthard
Published: (2012-03-01)

Drug–drug interaction analysis: Antituberculosis drugs versus antiretroviral drugs
by: Won Sriwijitalai, et al.
Published: (2019-01-01)